Figure 6
From: Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
Effect of Jak inhibitor AG490 on survival of nilotinib-insensitive cells in the presence of stroma. 3 × 106 lymphoma cells were seeded in 6 well tissue culture plates with irradiated MEFs and further treated with 5, 50 or 100 μM AG490 (A) or 20 nM nilotinib (B, C), respectively. In (B) and (C), in addition to nilotinib, treatment with 5, 50 or 75 μM AG490 was initiated as indicated by an arrow. As a control for the effect of AG490, single treatment with DMSO only (A) or 20 nM nilotinib (B, C) was analyzed, respectively. Fresh drug was added (depending on proliferation of the leukemia cells) every second or third day with the change of medium. Viability was assessed by propidium iodide uptake using a FACScan. Each point represents the average of triplicate values ± SEM.